肾骨颗粒联合复方骨肽治疗骨质疏松症的临床研究

目的探讨肾骨颗粒联合复方骨肽注射液治疗骨质疏松症的临床疗效。方法选取2017年5月—2018年5月在重庆市黔江中心医院进行治疗的136例骨质疏松症患者作为研究对象,根据用药的差别将患者分为对照组(68例)和治疗组(68例)。对照组患者肌肉注射复方骨肽注射液,4mL/次,1次/d;治疗组在对照组治疗的基础上口服肾骨颗粒,2g/次,3次/d。两组患者连续治疗4周。观察两组患者的临床疗效,比较治疗前后两组的视觉模拟量表评分(VAS)、Oswestry功能障碍指数(ODI)评分、骨质疏松症生活质量评分(OQOLS)、各部位骨密度和血清学指标。结果治疗后,对照组和治疗组的总有效率分别为80.88%、95.59%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者VAS评分、ODI评分显著降低,OQOLS评分显著升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组VAS评分、ODI评分和OQOLS评分明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者股骨颈、Ward氏三角区、腰椎L_(1-4)的BMD均显著升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组股骨颈、Ward氏三角区、腰椎L_(1-4)的BMD明显高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组血清抗酒石酸酸性磷酸酶(TRACP)、N端骨钙素(N-MID)水平显著降低,骨碱性磷酸酶(B-ALP)、I型前胶原氨基端前肽(PINP)、硬骨素(SOST)、骨钙素(BGP)水平显著升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组血清学指标明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论肾骨颗粒联合复方骨肽注射液治疗骨质疏松症能够显著改善患者相关症状,改善骨代谢指标和骨密度,提高患者生活质量,具有一定的临床推广应用价值。

Clinical study on Shengu Granules combined with compound ossotide in treatment of osteoporosis

Objective To investigate the clinical efficacy of Shengu Granules combined with Compound Ossotide Injection in treatment of osteoporosis.Methods Patients (136 cases) with osteoporosis in the Qianjiang Central Hospital of Chongqing from May 2017 to May 2018 were randomly divided into control (68 cases) and treatment (68 cases) groups according to the difference of medication. Patients in the control group were im administered with Compound Ossotide Injection, 4 mL/time, once daily. Patients in the treatment group were po administered with Shengu Granules on the basis of the control group, 2 g/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the VAS, ODI, OQOLS, BMD of different parts, and the serological indexes in two groups before and after treatment were compared.Results After treatment, the clinical efficacies in the control and treatment groups were 80.88% and 95.59%, respectively, and there were differences between two groups (P<0.05). After treatment, VAS and ODI scores in two groups were significantly decreased, but OQOLS were increased, and the difference was statistically significant in the same group (P<0.05). And the VAS, ODI, and OQOLS scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the BMD of femoral neck, Wards triangle, and lumbar vertebrae L_1-4 were significantly increased, and the difference were statistically significant in the same group (P<0.05). And the BMD of femoral neck, Wards triangle, and lumbar vertebrae L_1-4 in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum levels of TRACP and N-MID were significantly decreased, but the levels of B-ALP, PINP, SOST, and BGP were increased, and the difference was statistically significant in the same group (P<0.05). And the serological indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05).Conclusion Shengu Granules combined with Compound Ossotide Injection in treatment of osteoporosis can significantly improve the relevant symptoms of patients, and improve the bone metabolism indicators, BMD, and the quality of life, which has a certain clinical application value.